Rize Oncology Inc.
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.40% | -15.90% | 28.93% | -7.97% | 46.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.74% | -13.48% | 22.08% | 172.05% | 245.47% |
| Operating Income | 38.74% | 13.48% | -22.08% | -172.05% | -245.47% |
| Income Before Tax | 38.24% | 12.46% | -26.32% | -187.49% | -271.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.24% | 12.46% | -26.32% | -187.49% | -271.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.24% | 12.46% | -26.32% | -187.49% | -271.89% |
| EBIT | 38.74% | 13.48% | -22.08% | -172.05% | -245.47% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 43.40% | 19.44% | 38.64% | -48.48% | -89.29% |
| Normalized Basic EPS | 42.42% | 21.74% | 37.04% | -47.62% | -94.12% |
| EPS Diluted | 43.40% | 19.44% | 38.64% | -48.48% | -89.29% |
| Normalized Diluted EPS | 42.42% | 21.74% | 37.04% | -47.62% | -94.12% |
| Average Basic Shares Outstanding | 8.89% | 10.72% | 107.48% | 95.50% | 95.50% |
| Average Diluted Shares Outstanding | 8.89% | 10.72% | 107.48% | 95.50% | 95.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |